The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,296.00
Bid: 12,322.00
Ask: 12,324.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.016%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,296.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI)

27 May 2014 11:49

RNS Number : 1157I
Bank of America Merrill Lynch
27 May 2014
 



FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITYRule 8.5 of the Takeover Code (the "Code")

 

1.

KEY INFORMATION

(a)

Name of exempt principal trader:

Bank of America Merrill Lynch

(b)

Name of offeror/offeree in relation to whoserelevant securities this form relates:Use a separate form for each offeror/offeree

AstraZeneca PLC

(c)

Name of the party to the offer with which exempt principal trader is connected:

Pfizer Inc

(d)

Date dealing undertaken:

23/05/2014

(e)

Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

Yes

 

2.

DEALINGS BY THE EXEMPT PRINCIPAL TRADER

(a)

Purchases and sales

Class of relevant security

Purchases/sales

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

Common - ISIN GB0009895292

Purchase

855,516

43.28 GBP

42.17 GBP

Common - ISIN GB0009895292

Purchase

252,253

484.2 SEK

472.3 SEK

Common - ISIN GB0009895292

Sale

836,886

43.28 GBP

42.26 GBP

Common - ISIN GB0009895292

Sale

248,808

481.6 SEK

473.81 SEK

 

(b)

Derivatives transactions (other than options)

Class of relevant security

Product descriptione.g. CFD

Nature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

Common - ISIN GB0009895292

Swaps

Long

2

42.732 GBP

Common - ISIN GB0009895292

Swaps

Long

6

42.732 GBP

Common - ISIN GB0009895292

Swaps

Long

20

42.732 GBP

Common - ISIN GB0009895292

Swaps

Long

68

42.732 GBP

Common - ISIN GB0009895292

Swaps

Short

551

42.471 GBP

Common - ISIN GB0009895292

Swaps

Long

3

42.732 GBP

Common - ISIN GB0009895292

Swaps

Long

3

42.732 GBP

Common - ISIN GB0009895292

Swaps

Long

1

42.732 GBP

Common - ISIN GB0009895292

Swaps

Long

9

42.732 GBP

Common - ISIN GB0009895292

Swaps

Long

11

42.732 GBP

Common - ISIN GB0009895292

Swaps

Long

57

42.732 GBP

Common - ISIN GB0009895292

Swaps

Long

6

42.732 GBP

Common - ISIN GB0009895292

Swaps

Long

7

42.732 GBP

Common - ISIN GB0009895292

Swaps

Long

13

42.732 GBP

Common - ISIN GB0009895292

Swaps

Long

10

42.732 GBP

Common - ISIN GB0009895292

Swaps

Long

10

42.732 GBP

Common - ISIN GB0009895292

Swaps

Short

1,500

42.354 GBP

Common - ISIN GB0009895292

Swaps

Long

36,585

43.077 GBP

Common - ISIN GB0009895292

Swaps

Short

36,585

42.434 GBP

Common - ISIN GB0009895292

Swaps

Short

58,840

42.434 GBP

Common - ISIN GB0009895292

Swaps

Short

85,863

42.434 GBP

Common - ISIN GB0009895292

Swaps

Long

62,717

43.12 GBP

Common - ISIN GB0009895292

Swaps

Long

100,000

43.192 GBP

Common - ISIN GB0009895292

Swaps

Short

1,703

42.311 GBP

Common - ISIN GB0009895292

Swaps

Long

426

42.492 GBP

Common - ISIN GB0009895292

Swaps

Long

1,277

42.492 GBP

Common - ISIN GB0009895292

Swaps

Short

136

42.311 GBP

Common - ISIN GB0009895292

Swaps

Long

33

42.492 GBP

Common - ISIN GB0009895292

Swaps

Long

103

42.492 GBP

Common - ISIN GB0009895292

Swaps

Short

4,034

42.311 GBP

Common - ISIN GB0009895292

Swaps

Long

1,009

42.492 GBP

Common - ISIN GB0009895292

Swaps

Long

3,025

42.492 GBP

Common - ISIN GB0009895292

Swaps

Short

600

42.371 GBP

Common - ISIN GB0009895292

Swaps

Long

600

43.091 GBP

Common - ISIN GB0009895292

Swaps

Short

13,703

42.311 GBP

Common - ISIN GB0009895292

Swaps

Long

3,423

42.492 GBP

Common - ISIN GB0009895292

Swaps

Long

10,280

42.492 GBP

Common - ISIN GB0009895292

Swaps

Long

2,500

42.466 GBP

Common - ISIN GB0009895292

Swaps

Long

2,266

43.28 GBP

Common - ISIN GB0009895292

Swaps

Long

143

43.083 GBP

Common - ISIN GB0009895292

Swaps

Short

96

43.283 GBP

Common - ISIN GB0009895292

Swaps

Short

82,500

42.41 GBP

Common - ISIN GB0009895292

Swaps

Short

150,000

42.41 GBP

Common - ISIN GB0009895292

Swaps

Short

179

43.286 GBP

Common - ISIN GB0009895292

Swaps

Short

104

43.283 GBP

Common - ISIN GB0009895292

Swaps

Long

164,325

42.94 GBP

Common - ISIN GB0009895292

Swaps

Long

10,000

42.286 GBP

Common - ISIN GB0009895292

Swaps

Long

20,000

42.286 GBP

Common - ISIN GB0009895292

Swaps

Long

10,000

43.015 GBP

Common - ISIN GB0009895292

Swaps

Long

10,000

43.015 GBP

Common - ISIN GB0009895292

Swaps

Long

600

481.328 SEK

Common - ISIN GB0009895292

Swaps

Short

600

474.471 SEK

Common - ISIN GB0009895292

Swaps

Short

68,815

42.563 GBP

Common - ISIN GB0009895292

Swaps

Long

68,815

42.576 GBP

Common - ISIN GB0009895292

Swaps

Long

1,561

42.576 GBP

Common - ISIN GB0009895292

Swaps

Short

1,000

42.318 GBP

Common - ISIN GB0009895292

Swaps

Long

1,000

42.076 GBP

 

(c)

Options transactions in respect of existing securities

(i)

Writing, selling, purchasing or varying

Class ofrelevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number ofsecurities to which option relates

Exercise priceper unit

Typee.g. American, European etc.

Expiry date

Option money paid/ received per unit

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

 

(ii)

Exercising

Class of relevant security

Product descriptione.g. call option

Number of securities

Exercise Price per unit

N/A

N/A

N/A

N/A

 

(d)

Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealinge.g. subscription, conversion

Details

Price per unit (if applicable)

N/A

N/A

N/A

N/A

 

The currency of all prices and other monetary amounts should be stated.Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional classof relevant security dealt in.

 

3.

OTHER INFORMATION

 

(a)

Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state "none"

None

 

(b)

Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) The voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none"

None

 

Date of disclosure:

27/05/2014

Contact name:

Stacy Otieno

Telephone number:

0207 995 1335

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory InformationService and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.The Panel's Market Surveillance Unit is available for consultation in relation to the Code'sdealing disclosure requirements on +44 (0)20 7638 0129.The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FERBGGDURSDBGSR
Date   Source Headline
28th May 20217:00 amRNSTagrisso approved in EU in early lung cancer
27th May 20214:41 pmRNSSecond Price Monitoring Extn
27th May 20214:36 pmRNSPrice Monitoring Extension
27th May 20217:00 amRNSAstraZeneca prices a EUR800m bond offering
26th May 20219:24 amRNSStabilisation Notice
26th May 20217:00 amRNSAstraZeneca prices a $7bn bond offering
25th May 20217:00 amRNSEMTN programme update - publication of Prospectus
21st May 20217:00 amRNSVaxzevria COVID-19 vaccine approved in Japan
18th May 20213:30 pmRNSDirector/PDMR Shareholding
11th May 20212:00 pmRNSResult of AGM
11th May 20211:55 pmRNSShareholders vote in favour of Alexion acquisition
7th May 20217:00 amRNSImfinzi + tremelimumab showed survival in POSEIDON
5th May 20216:30 pmRNSHolding(s) in Company
4th May 20213:00 pmRNSTotal Voting Rights
4th May 20217:00 amRNSFarxiga approved in the US for CKD
30th Apr 20217:00 amRNSAZN: First quarter 2021 results
26th Apr 20217:10 amRNSSelumetinib recommended for EU approval in NF1
26th Apr 20217:05 amRNSTagrisso adjuvant receives positive CHMP opinion
26th Apr 20217:00 amRNSNirsevimab Phase III trial met primary endpoint
16th Apr 202112:00 pmRNSUS clearance of proposed acquisition of Alexion
14th Apr 20217:00 amRNSTagrisso approved in China in early lung cancer
12th Apr 20211:00 pmRNSCircular and notice of general meeting
12th Apr 20217:00 amRNSUpdate on Farxiga COVID-19 DARE-19 Phase III trial
1st Apr 20213:00 pmRNSTotal Voting Rights
30th Mar 202112:15 pmRNSNotice of AGM
25th Mar 20213:00 pmRNSDirector/PDMR Shareholding
25th Mar 20217:00 amRNSAZD1222 US Ph3 primary analysis confirms efficacy
22nd Mar 20217:00 amRNSAstraZeneca US vaccine trial met primary endpoint
16th Mar 20217:05 amRNSDivestment of Viela shareholding completed
16th Mar 20217:00 amRNSUS supply agreement for additional AZD7442 doses
9th Mar 20213:00 pmRNSDirector/PDMR Shareholding
4th Mar 20213:00 pmRNSDesignation of EU home member state
3rd Mar 20217:00 amRNSUS court decision favours Symbicort patents
2nd Mar 20217:00 amRNSFurther update on roxadustat US regulatory review
1st Mar 20213:00 pmRNSTotal Voting Rights
22nd Feb 20217:00 amRNSVoluntary withdrawal Imfinzi US bladder indication
17th Feb 20217:00 amRNSLynparza: IDMC recommend early analysis of OlympiA
16th Feb 202111:15 amRNSFiling of Form 20-F with SEC
15th Feb 20213:00 pmRNSDirector/PDMR Shareholding
15th Feb 202111:00 amRNSAnnual Financial Report
11th Feb 20217:01 amRNSAstraZeneca Non-Executive Board changes
11th Feb 20217:00 amRNSAZN: full-year 2020 results
10th Feb 20217:00 amRNSDivestment of Crestor in Europe completed
5th Feb 20217:00 amRNSUpdate on KESTREL Phase III trial for Imfinzi
4th Feb 20217:00 amRNSForxiga approved in China for heart failure
1st Feb 20213:00 pmRNSTotal Voting Rights
1st Feb 202112:15 pmRNSAstraZeneca agrees to divest Viela shareholding
1st Feb 20217:00 amRNSCOVID-19 vaccine authorised for use by the EU
29th Jan 20213:16 pmRNSCOVID-19 vaccine receives positive opinion in EU
26th Jan 20213:00 pmRNSBlock listing application

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.